Reactions Weekly

, Volume 1694, Issue 1, pp 40–40 | Cite as


Pneumonitis: 4 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A case series described three women and a man aged 50−72 years, who developed pneumonitis following the administration of bleomycin, carmustine, etoposide, cytarabine, melphalan, pembrolizumab or rituximab [routes, not all durations of dosages, treatment to reactions onsets stated].

Patient 1: A 50-year-old woman, who had stage IV primary mediastinal B-cell lymphoma, started receiving treatment with pembrolizumab 200mg every three weeks. Her previous treatments included the REPOCH regimen comprising rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin, the R-DHAP regimen including rituximab, dexamethasone, cytarabine and cisplatin, and palliative radiotherapy. At 12 weeks following the initiation of pembrolizumab, she developed cough, wheezing and...


  1. Nishino M, et al. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. British Journal of Haematology 180: 752-755, No. 5, Mar 2018. Available from: URL: - USACrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations